Beijing, Sept 4, 2026 — China’s Center for Drug Evaluation (CDE) proposed adding MRO-001HS capsules, developed by Maiba Pharmaceutical (Hangzhou) Co., Ltd., to the “Care Plan Extension” pilot for encouraging innovative drug R&D for rare diseases, targeting amyotrophic lateral sclerosis (ALS), with a public comment deadline of Sept 11, 2026.
Program Snapshot
| Attribute | Detail |
|---|---|
| Program | Care Plan Extension (Rare Disease Innovative Drug R&D Incentive Pilot) |
| Product | MRO-001HS Capsules |
| Applicant | Maiba Pharmaceutical (Hangzhou) Co., Ltd. |
| Indication | Amyotrophic lateral sclerosis (ALS) |
| Comment deadline | Sept 11, 2026 |
| Contact | zhaona@cde.org.cn |
Clinical Context
Amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease or motor neuron disease, is a progressive neurodegenerative disorder that destroys upper and lower motor neurons, leading to muscle atrophy, paralysis and typically death from respiratory failure within three to five years of diagnosis. Therapeutic options remain severely limited—riluzole and edaravone offer only modest slowing of progression, while newer agents such as tofersen address narrow genetic subgroups. ALS is included in China’s official catalog of rare diseases, where the prevalence of roughly 3 to 5 per 100,000 implies a patient population well over 100,000 nationwide, most of whom lack access to disease-modifying therapy.
Market Impact Analysis
The proposed inclusion signals CDE’s expanding use of its rare disease incentive framework to pull innovative candidates into a fast-track regulatory environment. The Care Plan Extension builds on the original Care Plan pilot by broadening eligibility and reinforcing a package of development incentives—enhanced preclinical and clinical communication channels, rolling review of data submissions, and potential priority pathways—that materially de-risk ALS programs for small and mid-cap biotechs.
For Maiba Pharmaceutical, a Hangzhou-based developer, the pilot listing positions MRO-001HS alongside a growing cohort of China-originated CNS and rare disease assets seeking differentiated regulatory support rather than competing head-to-head in crowded oncology indications. The economics of ALS drug development are challenging—small trial populations, heterogeneous progression and limited pricing power—yet the designation improves both the regulatory timeline and the asset’s partnering profile, a critical consideration for biotechs courting global license deals.
The one-week comment window, shorter than typical CDE public consultations, suggests regulators view the submission as aligned with the pilot’s urgent mandate to accelerate therapies for life-threatening rare diseases with few existing options, rather than a contested listing.
Forward-Looking Statement
Industry observers expect MRO-001HS to progress into pivotal-stage clinical development under the pilot’s enhanced regulatory support, with the Care Plan Extension designation potentially compressing the timeline from clinical trials to NDA acceptance by several quarters if the program generates positive data. Successful development in ALS could establish a proof-of-concept for the extended incentive framework in neurodegenerative rare diseases, encouraging additional filings targeting motor neuron disorders and related indications. The pilot also reinforces China’s strategic push to localize rare disease innovation, reducing dependence on imported therapies for conditions like ALS. Final inclusion in the pilot is anticipated following the Sept 11 comment deadline, barring substantive objections.-China Health Reform Pulse
Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/3efc47502efbabbd6d4231e145718966